Skip to Main Content

Paper Details

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02.
Neurooncol Adv
8
2020
Author NameAffiliation
John G KuhnUniversity of Texas
Wai-Kwan Alfred YungThe University of Texas MD Anderson Cancer Center
Wai-Kwan Alfred YungThe University of Texas MD Anderson Cancer Center
Minesh P MehtaMiami Cancer Institute
Kenneth AldapeNational Cancer Institute, National Institutes of Health
Kenneth AldapeNational Cancer Institute, National Institutes of Health
Michael D PradosUniversity of California san francisco
Michael D PradosUniversity of California san francisco
Timothy F CloughesyUniversity of California los angeles
Timothy F CloughesyUniversity of California los angeles
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
  • 1 - 11

Datasets

Release 1.2